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The production of phosphatidic acid (PA) from phospho- Abstract When rat polymorphonuclear neutrophils (PMN) 
were treated with N-formyI-Met-Leu-Phe (fMLP), the release lipase D (PLD)-catalyzed hydrolysis of phosphatidylcholine s 
of araehidonie acid in preference to other fatty acids was a rapid and widespread response of cells stimulated with di- 
observed. Levels of arachidonic acid reached a plateau within verse agonists, and is implicated in a broad spectrum of 
5 rain, and were accompanied by an ,-~ 4-fold increase in in vitro physiological and pathological processes, such as exocytosis, 
phospholipase (PL) A2 and PLD activities in PMN lysates, mitogenesis, oncogenesis and inflammation (reviewed in [4]). 
Treatment of PMN with ethanol (an inhibitor of PLD-mediated There are also several lines of evidence to suggest that arachi- 
phosphatidic acid formation), propranolol (a phosphatiflic acid donic acid release correlates with PLD activation. Arachidon- 
phosphatase inhibitor), or 4-bromophenaeylbromide (a PLA2 ic acid release by activated cells is reported to be accompanied 
inhibitor), each suppressed fMLP-stimulated araehidonate re- by the increase in PLD activity and inhibition of PLD by 
lease. Treatment with RHC-80267 (a diaeylglyeerol ipase ethanol is associated with the decrease in arachidonic acid 
inhibitor), however, had no such effect. The eytosolie PLA2 
release [5-10]. To account for these observations, ome inves- (ePLA2) inhibitor, araehidonoyl trifluoromethyl ketone, sup- 
pressed PLA2 activity in PMN homogenates and araehidonate tigators have proposed that the PA generated by the PLD 
release by fMLP-treated PMN. These results suggest that reaction is converted to diacylglycerol (DG) by PA phosphat- 
fMLP-elicited arachidonate release is mediated by cPLA2 but ase, and that arachidonic acid is released from DG by DG 
not diacylglycerol lipase, and that the activation of cPLA2 is lipase [6,7]. In contrast to this 'indirect' model for arachidonic 
downstream of the PLD-dependent signaling pathway, acid release via DG, other investigators have proposed that 
arachidonic acid is 'directly' released from phospholipids by 
Key words: Phospholipase A2; Phospholipase D; PLA2 [8-10]. In the latter case, certain product(s) of the PLD- 
Neutrophil; Formyl-Met-Leu-Phe; Arachidonic acid; Rat dependent signaling pathway must act as modulator(s) to reg- 
ulate PLA2 activity. 
Several reports have shown that activation of PLD is indis- 
1. Introduction pensable for several cellular responses in polymorphonuclear 
neutrophils (PMN) [11-15]. A number of agonists have also 
The 85-kDa cytosolic phospholipase A2 (cPLA2), an ara- been reported to activate cPLA2, leading to arachidonic acid 
chidonic acid-preferential PLA2 isozyme, is distributed release in PMN [16-20]. Therefore PMN represent a useful 
throughout a wide variety of animal tissues and cells. It pref- model system for addressing the functional relationship be- 
erentially hydrolyses phospholipids containing arachidonic tween cPLA2 and PLD after stimulation with a variety of 
acid at the sn-2 position, translocates from the cytosol to stimuli. We now report hat the selective release of arachidon- 
intracellular membrane compartments in response to a sub- ic acid, which is predominantly regulated by cPLA2, is atte- 
micromolar order of intracellular Ca 2+ concentration, and is nuated by inhibiting the PLD-dependent signaling pathway in 
activated by phosphorylation via mitogen-activated protein N-formyl-Met-Leu-Phe (fMLP)-stimulated rat PMN, thereby 
(MAP) kinase (reviewed in [1-3]). On the basis of these lea- providing evidence for a functional correlation between PLD 
tures, cPLA2 is believed to regulate arachidonic acid release and cPLA2. 
by mammalian cells in response to stimuli that mobilize in- 
tracellular Ca 2+ and activate MAP kinase. 2. Materials and methods 
*Corresponding author. Fax: (81) (3) 3784-8245. 2.1. Materials 
Female Sprague-Dawley rats (weighing 190-220 g) were obtained 
Abbreviations: cPLA2, cytosolic phospholipase A2; PLD, phospho- from Japan Clear (Tokyo, Japan). Histopaque 1077, fMLP, cytochal- 
lipase D; fMLP, N-formyl-Met-Leu-Phe; PMN, polymorphonuclear asin B, NazVO4, 4-bromophenacylbromide (pBPB), 1-palmitoyl-2- 
neutrophils; AACOCF3, arachidonyl trifluoromethyl ketone; PA, arachidonoyl-sn-glycero-3-phosphocholine, and acid phosphatase 
phosphatidic acid; PEt, phosphatidylethanol; PC, phosphatidylcho- (from white potato, type VII) were purchased from Sigma (St. Louis, 
line; pBPB, 4-bromophenacylbromide; DG, diacylglycerol; MAP MO). Arachidonyl trifluoromethyl ketone (AACOCF3) was pur- 
kinase, mitogen-activated protein kinase; HBSS, Hanks' balanced salt chased from Calbiochem-Novabiochem International (San Diego, 
solution; 1-BODIPY-PC, 2-decanoyl-l-(O-(ll-(4,4-difluoro-5,7-di- CA). 9-Anthryldiazomethane and RHC-80267 were purchased from 
methyl-4-bora-3a,4a-diaza-S-indacene-3-propionyl)amino)undecyl)-sn- Fu akoshi (Tokyo, Japan). 2-Decanoyl-l-(O-(ll-(4,4-difluoro-5,7-di- 
glycero-3 phosphocholine methyl-4-bora-3a,4a-diaza-S-indacene-3-propionyl)amino)undecyl)-sn- 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
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glycero-3-phosphocholine (1-BODIPY-PC) is a product of Molecular 2.5. Preparation ofhomogenates offMLP-stimulated PMN 
Probes (Eugene, OR). PMN, adjusted to 3.75x 107 and 1.25 × 10 s cells/ml for assaying 
PLA2 and PLD activities, respectively, were resuspended in 20 mM 
2.2. Preparation of PMN Tris-HCl, pH 7.4, containing 2 mM dithiothreitol, 1 mM EDTA, 
Preparation of PMN was principally according to a method re- 1 mM EGTA, 1 mM NaaVO4, and 1 mM PMSF at 4°C. The cells 
ported by Boyum [21]. Rats were injected intraperitoneally with 25 were then disrupted using a Model UR-20P sonicator (TOMY, To- 
ml of 3% (w/v) sodium caseinate. After 16 h, 15 ml of Hanks' bal- kyo, Japan) at 20 W for 3 s. Any undisrupted cells and cell debris 
anced salt solution (HBSS) containing 1mM EDTA (HBSS/EDTA) were removed by centrifugation at 18 000 x g for 1 min at 4°C. Super- 
was injected intraperitoneally, and peritoneal cells were collected by natants were recovered and used for PLD assay. For PLA2 assay, this 
centrifugation at 200xg for 10 min at 15°C. After two washes, the fraction was further centrifuged at 100000xg for 60 min at 4°C to 
cells were resuspended in HBSS containing 0.5 mM EDTA and 1.25 obtain a cytosol fraction. 
mg/ml BSA (HBSS/BSA) at 1.5 × 107 cells/ml. Mononuclear cells were 
removed by step-wise density gradient centrifugation with Histopaque 2.6. PLA2 assay 
1077 at 500×g for 30 min at 15°C. The resulting pellet containing PLA2 activity was assayed by measurement of free arachidonic acid 
PMN was recovered, and the remaining erythrocytes were removed by released [23]. The reaction mixture consisted of 100 mM Tris-HC1, pH 
washing with 155 mM NH4C1, 10 mM KHCO3 and 0.1 mM EDTA, 9.0, 4 mM CaC12, 1 mg/ml BSA, 12.5 I.tM 1-palmitoyl-2-arachidonoyl- 
pH 7.2. The cells were washed twice, resuspended in HBSS/BSA and sn-glycero-3-phosphocholine, and PMN homogenate soluble fraction 
kept on ice until use. The purity of the PMN was checked by Giemsa (9.4 × 105 cell equivalents). After incubation for 20 min at 37°C, the 
staining, and their viability was determined by trypan blue dye exclu- released arachidonic acid was extracted, and levels determined using 
sion. PMN with a purity of 90.8 + 0.7% (mean + S.E.M.; n = 7) were high performance liquid chromatography (HPLC), as described 
used in this study, above. 
2.3. Stimulation of PMN 2. Z Phosphatase treatment of PMN homogenate 
To a suspension of 1.25 × 10 z cells/ml PMN, 1.26 mM CaC12, 0.49 PMN homogenates were prepared by sonication in cell lysis buffer 
mM MgCI2, 0.41 mM MgSO4 and 5 gg/ml cytochalasin B were composed of 20 mM Tris-HC1, pH 7.4, 2 mM dithiothreitol, 1 mM 
added, and the mixture was preincubated for 5 min at 37°C. PMN EDTA and 1 mM EGTA. Then the homogenates were incubated for 
were then stimulated by 0-1250 nM fMLP and incubated for up to 15 10 min at 37°C with either 18 units/ml acid phosphatase or 1 mM 
min at 37°C. The effects of the pretreatment with various inhibitors Na3VO4 in 50 mM 2-[N-morpholino]ethanesulfonic acid (pH 6.0) and 
on PMN were determined, as described in the appropriate figure 1 mM MgC12. After the incubation, cPLA2 activity was assessed as 
legends. Reactions were stopped by dipping the tubes into an ice- described above. 
water bath. 
2.8. PLD assay 
2.4. Fatty acid analysis PLD activity was assayed principally according to a method re- 
0.5 nmol of n-heptadecanoic acid and 2.5 nmol of 2,6-bis(1,1-di- ported by Jones et al. [24]. Briefly, 12.5 gl of reaction mixture, com- 
methylethyl)-4-methylphenol were added as an internal standard and posed of 60/aM 1-BODIPY-PC, 0.12 mM n-octyl-glucopyranoside, 96 
anti-oxidant, respectively, followed by the addition of 1.25 ml of mM NaC1, 15 mM 2-[N-morpholino]ethanesulfonic acid (pH 6.0), 
Dole's reagent [22]. Free fatty acids were extracted into the n-hepta- 6 mM piperazine-N,N'-bis[2-ethanesulfonic acid] (pH 6.5), 3 mM 
decanoic acid layer, dried under a nitrogen stream and then converted EGTA, 0.6 mM EDTA, 24 mM glycerol-2-phosphate (pH 7.0), 0.6 
into fluorescent derivatives by the addition of 100 I-tl of 0.1 mg/ml 9- mM dithiothreitol and 5 gl of PMN homogenates, was incubated for 
anthryldiazomethane dissolved in methanol/ethyl acetate (9:1, v/v), up to 30 min at 30°C. The reaction was stopped by dipping the tubes 
followed by incubation for 1 h in the dark at room temperature, into an ice-cold water bath. Then 5 gl of the reaction mixture was 
Free fatty acids were analyzed on a Capcell Pak C18 column spotted onto silica gel plates (TLC plates silica gel 60 without ftuo- 
(AG120, 4.6x250 mm, S-5 gm; Shiseido, Tokyo, Japan) at 35°C, rescent indicator, Art. 5641; Merck) and developed with chloroform/ 
using a solvent system of acetonitrile/2-propanol/water (80:16:4, methanol/water/acetic acid(65:35:4:1, v/v). The spots were visualized 
v/v) at a flow rate of 1.2 ml/min. The 9-anthryldiazomethane deriv- with the aid of UV lamp, and spots corresponding to PA and phos- 
atives were detected with the aid of a fluorescence detector (excitation phatidylethanol (PEt) were scraped off and extracted with 1.5 ml of 
at 365 nm and emission at 412 nm). ethanol. After removal of the silica gel by centrifugation, the fluores- 
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Fig. 1. Fatty acid release by fMLP-stimulated PMN. A: PMN were incubated in the presence of 50 nM fMLP for the indicated periods and 
the amounts of free fatty acids, including arachidonic acid (open circles), linoleic acid+myristic a id (open triangles), oleic acid (open squares), 
palmitoic acid (closed triangles) and stearic acid (closed squares) were quantified, as described in Section 2. B: PMN were incubated with the 
indicated concentrations of fMLP for 1 min at 37°C, and the levels of free arachidonic acid were quantified. Data are expressed as the mean + 
S.E.M. of six independent experiments, each of which was carried out in duplicate. **P < 0.01 versus without fMLP. 
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, - ,  Fig. 2. PLAz activity in 100000×g supernatants of PMN lysates. 
Z A ** A: Activation of PLA2 activity by fMLP. PLA2 activity in the 
100000×g supernatants of PMN homogenates, which were pre- 
IX. 0 .4  pared from PMN that had been stimulated for 1 min with various 
O concentrations of fMLP, were assayed as described in Section 2. 
Data are expressed as the mean + S.E.M. of five independent experi- t-- 
"~ 0 .3  ments, each of which was carried out in duplicate. **P< 0.01 versus 
-... without fMLP. B: Effect of AACOCF3 on PLA2 activity. 
0 lO0000×g supernatants of homogenates prepared from PMN be- 
I:: fore and after stimulation for 1 min with 1250 nM fMLP were incu- 
O. 0 .2  bated with the indicated concentrations of AACOCF3 for 10 min at 
37°C, and then assayed for PLA2 activity. Data are expressed as 
.> _ ~ the mean + S.E.M. of three independent experiments, each of which 
"~ 0.1 was carried out in duplicate. *P<0.05 and **P<0.01 versus with- / /  out AACOCFa C: Effect of AACOCF3 on the release of arachi- donic acid by fMLP-stimulated PMN. PMN, pretreated with the in- 
dicated concentrations of AACOCFa for 20 min at 37°C, were 
IX. 0 ...t_ ...L_ _ incubated with 50 nM fMLP for 5 min at 37°C. The free fatty acids 
released were analyzed. Data are expressed as the mean + S.E.M. of 
0 10 50  250  1250 five independent experiments, each of which was carried out in du- 
fMLP (nM) plicate. **P< 0.01 versus without AACOCF3. 
<__ 
B 
o- 0.1 • Unstimulated Cells 
• 2.9. Statistical analysis 
• ** Data are expressed as the mean + S.E.M. of more than three inde- 
Z ** pendent experiments, each of which was carried out in duplicate. 
n Statistical analysis was performed using an unpaired Student's t-test. 
n 0.4 fMLP-stimulated Cells % 
"-- 3. Results e- 
. ~  
E 0.3 
3.1. Free fatty acid release in fMLP-stimulated PMN 
E ** When PMN were stimulated with 50 nM fMLP, levels of 
-~  free arachidonic acid increased, reaching a maximum and pla- 
0 .2  teauing at 103.7 + 6.9 pmol/106 cells after 3 min (Fig. 1A). In 
• -> ** contrast, levels of other fatty acids, including linoleic, myris- 
_ ~  tic, oleic, palmitoic and stearic acids, did not change appreci- 
0.1 ably. The release of arachidonic acid was dependent upon the 
e ,  concentration of fMLP, having a minimal effect at 10 nM, 
0. and causing a maximal release of 115.6+4.8 pmol/106 cells 
0 - ..a-- . - t_  at 1250 nM (Fig. 1B). No appreciable increase in fatty acids 
0 0.04 0.2 1 5 other than arachidonic acid was observed at any fMLP con- 
centration (data not shown). 
AACOCF3 (HM) 
C 3.2. PLA2 activity in fMLP-stimulated PMN 
PLA2 activity in the 100000×g supernatant of PMN 
150 • homogenate increased following stimulation with fMLP, 
~"  from a basal release of 0.10 + 0.02 pmol of arachidonic acid/ 
120 min/106 cell equivalents to 173% at 0.17_+0.04 and 347% at 
o 0.35 + 0.05 pmol/min/106 cell equivalents at 50 and 1250 nM 
~O fMLP, respectively (Fig. 2A). Thus, activation of PLA2 activ- 
00  ity in the 100 000 × g supernatant of PMN homogenate paral- o 
Eo. leled the increase in arachidonic acid release (Fig. I B). PLA2 
,~. 60  ** activity in the 100000xg supernatants of homogenates pre- 
-O pared from unstimulated and fMLP-stimulated PMN (Fig. 
eq 2B) were inhibited by the cPLA2-specific inhibitor, AACOCFa 
O 30 [25], in a similar dose-dependent manner: PLA2 activity in the 
100 000xg supernatants of unstimulated PMN homogenates 
fell from 0.10 to 0.048 (47%), and to 0.022 (21%) pmol/min, 
0 I I I I 
and that of fMLP-stimulated PMN homogenates fell from 
0 5 10 15 20 0.36 to 0.19 (52%), and to 0.037 (10%) pmol/min at 0.2 and 
5 /aM AACOCFa,  respectively. Thus, PLA2 activity in the 
AACOCF3 (NM) PMN homogenates i  most probably attributable to cPLAz. 
cence intensity of the reaction products was determined using a fluo- The increased cPLA2 activity in fMLP-stimulated PMN 
rescence spectrophotometer at an excitation wavelength of 507 nm returned to the basal level when PMN homogenates were 
and emission wavelength of 514 nm. treated with acid phosphatase; cPLA2 activities in lysates of 
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Fig. 3. Effects of inhibitors of the PLD pathway on arachidonic acid release by fMLP-stimulated PMN. PMN were pretreated with the indi- 
cated concentrations of ethanol (A, B), propranolol (C) and RH-80267 (D) for 5 min at 37°C and incubated with 50 nM fMLP for 5 rain at 
37°C. Arachidonic acid release by cells (A, C, D) and PLD activity in cell lysates as assessed by the formation of phosphatidic acid (open cir- 
cles) and PEt (closed circles) (B) were quantified as described in Section 2. Data are expressed as the mean _+ S.E.M. of six (A and C), five (B) 
and four (D) independent experiments, each of which was carried out in duplicate. *P < 0.05 and **P < 0.01 versus without each inhibitor. 
unstimulated cells, those activated with 1250 nM fMLP, and 0.024 + 0.004 (n = 5; P< 0.01) pmol/min/106 cell equivalents 
those activated with fMLP and then treated with acid phos- after stimulation with 10 and 50 nM fMLP, respectively. 
phatase were 0.139+0.009, 0.287_+0.031 (P<0.01 versus un- When 2% ethanol, which has often been used to assess the 
stimulated cells), and 0.153 + 0.051 (P < 0.05 versus fMLP-ac- involvement of PLD in cellular functions by inhibiting PA 
tivated cells without phosphatase treatment) pmol/min/106 cell production with a reciprocal formation of PEt through trans- 
equivalents (n = 3), respectively. These results imply that the phosphatidylation [11-15], was added to the PLD assay mix- 
increase in cPLA2 activity in fMLP-stimulated PMN results ture, both 1-BODIPY-PEt and 1-BODIPY-PA were formed 
from the phosphorylation, as has been reported [1-3,19]. with a ratio of 7:3. Under this assay condition, production of 
1-BODIPY-PEt and 1-BODIPY-PA increased in parallel in 
3.3. PLD activity in fMLP-stimulated PMN response to the incremental concentrations of fMLP (data 
PLD activity in the PMN homogenates was measured by not shown). 
assessing the conversion of fluorescence-labeled PC (1-BODI- 
PY-PC) to 1-BODIPY-PA. PLD activity in unstimulated 3.4. Effect of inhibitors 
PMN, with the production of 0.008 _+0.001 pmol of PA/min/ Ethanol reduced arachidonic acid release by fMLP-stimu- 
106 cell equivalents (n = 5), increased to 234% with lated PMN, with an ICs0 of 0.3% (Fig. 3A). cPLA2 activity in 
0.019_+0.003 (n-- 5; P<0.05), and to 289% with the 100000×g supernatant of fMLP-stimulated PMN homo- 
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nied by reciprocal formation of PEt (Fig. 3B). Propranolol, 
--'~" 100  ~ T  A which inhibits the hydrolysis of PA to DG [26], also reduced 
arachidonic acid release by fMLP-stimulated PMN, with an 
80  IC50 of 25 txM (Fig. 3C). Neither ethanol nor propranolol, at 
the concentrations u ed here, affected cPLA2 activity appreci- 
ably when added directly to the cPLA2 assay mixture (data 
60  not shown). In contrast, RHC-80267, a DG lipase inhibitor 
[27], only a suppressive on exhibited minimal effect arachidon- 
40  ~**  ** ic acid release by fMLP-stimulated PMN (Fig. 3D). The 
xl" ~ ~ non-specific PLA2 inhibitor, pBPB [2], inhibited both arach- 
20  idonic acid release by fMLP-stimulated PMN (Fig. 4A) and 
~,  PLA2 activity in the homogenate of fMLP-stimulated PMN 
0 I I / I (Fig. 4B), with a similar IC50 of 7 IxM, and without any 
appreciable effect on PLD activity (Fig. 4C). The cPLA2-spe- 
cific inhibitor, AACOCF3 [25], inhibited arachidonic acid re- 
0.3 lease by fMLP-stimulated PMN with an IC50 of 7 gM (Fig. 
>, Z ~ 2C). These data suggest hat fMLP-stimulated arachidonic 
.>_ fl_ acid release is mediated by cPLA2 but not DG lipase, and 
~ 0.2 that the activation of cPLA2 is downstream of the PLD-de- 
pendent signaling pathway. 
n E 0.1 4. Discussion 
,~  The release of arachidonic acid in preference to other fatty 
acids has been shown to occur in several cells such as A23187- 
0 I I I I 
stimulated rabbit alveolar macrophages [28], thrombin-stimu- 
o" 0.04 C lated human platelets [29], and A23187-stimulated human 
PMN [30,31]. To determine whether or not arachidonic acid 
is released selectively, it is important to discover what types of 
• "~ ~ 0.03 phospholipase(s) are involved. In the work presented here, we 
have quantified the absolute amounts of each fatty acid re- 
~,.. leased from rat PMN upon stimulation with fMLP, by means 
t::l "~ 0.02 of fluorescence-based HPLC, and have confirmed the strict 
-- I  
0. "E specificity of fatty acid liberation for arachidonic acid. This 
o arachidonic acid release was suppressed significantly by 
E 0.01 cPLA2 inhibitors, including pBPB and AACOCF3. These ob- 
servations uggest hat cPLA2, an arachidonoyl-preferential 
0 = I I : PLA2 isozyme, is the predominant enzyme that regulates 
0 10 20 30 40 arachidonic acid release by fMLP-stimulated rat PMN. This 
is consistent with recent reports that demonstrate he involve- 
pBPB (pM) ment of cPLA2 in the arachidonate metabolism of human 
neutrophils [16-20]. 
Fig. 4. Effects of pBPB on arachidonic acid release and in vitro We have shown here that when PMN were stimulated with 
PLA2 and PLD activity. PMN were pretreated with the indicated 
concentrations ofpBPB for 10 min at 37°C, and incubated with 50 fMLP, both cPLA2 and PLD activity in the homogenates 
nM fMLP for 5 min at 37°C. The free fatty acids released (A), increased in parallel, and were accompanied by a concomitant 
PLA2 activity (B) and PLD activity (C) were measured as described arachidonic acid release. The latter was reduced by the addi- 
in Section 2. Data are expressed as the mean+ S.E.M. of three (B) tion of either ethanol, which inhibits PA formation through 
and five (A and C) independent experiments, each of which was car- 
ried out in duplicate. **P< 0.01 versus without pBPB. transphosphatidylation [11-15], or AACOCF3 [25] and pBPB 
[2], as inhibitors of cPLA2 and PLA2s, respectively, but not by 
RHC-80267, a DG lipase inhibitor [27]. These results suggest 
genates decreased from 0.368 + 0.050 pmol/min/106 cell that in rat PMN PLD is functionally linked to cPLA2, but not 
equivalents (n = 4) to 0.226 + 0.019 (P < 0.05) and to DG lipase. Propranolol, generally used as a PA phospha- 
0.174+0.017 pmol/min/106 cell equivalents (P<0.01) when tase inhibitor [26], also suppressed arachidonic acid release, 
the cells were treated with fMLP in the presence of 0.5 and suggesting that certain products generated after the PLD/PA 
1% ethanol, respectively, cPLA2 activity in homogenates of phosphatase pathway are involved in cPLAz activation. Since 
PMN exposed to fMLP in the presence of 1% ethanol, which DG, a product of the PLD/PA phosphatase pathway, is a 
was comparable to that in homogenates of unstimulated potent activator of protein kinase C [32], subsequent kinases, 
PMN, was insensitive to acid phosphatase treatment (data such as MAP kinase, may be responsible for cPLA2 activa- 
not shown). The ethanol-induced inhibition of arachidonic tion. A correlation between PLD and the ras/MAP kinase 
acid release and in vitro cPLA2 activity paralleled that of pathway has been reported [33]. Indeed, the 3.5-fold increase 
PLD activity in fMLP-stimulated PMN homogenates: etha- in in vitro cPLA2 activity in PMN observed following stimu- 
nol prevented PA formation with an IC50 of 0.5%, accompa- lation with fMLP is consistent with the general understanding 
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that cPLA2 activity is augmented several-fold by MAP kinase- [9] Ryder, N.S., Talwar, H.S., Reynolds, N.J., Voorhees, J.J. and 
dependent phosphorylation [1-3], and with the observation Fisher, G.J. (1993) Cell. Signal. 5, 787 794. 
[10] Hashizume, T., Taniguchi, M., Sato, T. and Fujii, T. (1994) 
that fMLP-induced MAP kinase activation in human neutro- Biochim. Biophys. Acta 1221, 179-184. 
phils leads to cPLA2 phosphorylation and activation [19]. [11] Mullman, T.J., Siegel, M.I., Egan, R.W. and Billah, M.M. (1990) 
This speculation is further supported by the observation J. Immunol. 144, 1901-1908. 
that increased cPLA2 activity was reversed by treatment of [12] Agwu, D.E., McPhail, L.C., Chabot, M.C., Daniel, L.W., Wykle, 
R.L. and McCall, C.E. (1989) J. Biol. Chem. 264, 1405-1413. 
the PMN homogenate with acid phosphatase. [13] Reinhold, S.L., Prescott, S.M., Zimmerman, G.A. and Mclntyre, 
Whereas AACOCF3 completely inhibited cPLA2 activity in T.M. (1990) FASEB J. 4, 208 214. 
vitro, it inhibited arachidonic acid release by fMLP-stimulated [14] Bauldry, S.A., Bass, D.A., Cousart, S.L. and McCall, C.E. (1991) 
PMN only partially (,~60%), even when used in excess J. Biol. Chem. 266, 4173-4179. 
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